Events & Ideas

Our Work

Prescription Medicines

Making MDMA A Medicine: Analysis of the 8-factors of the Controlled Substances Act for the Abuse Potential of MDMA

Coker A, Yazar-Klosinski B, Emerson A, Doblin R, Coe M, Henningfield JA If MDMA is approved for therapeutic use by the FDA, then it must be removed from Schedule I and placed in the most appropriate schedule based in part on analysis of 8 factors listed in the CSA. Although further analyses will be considered… Read More

Prescription Medicines

The 15th Annual Pain Therapeutics Summit

NOVEMBER 1–2, 2021 | WASHINGTON, DC The Potential Role for Psychedelic Drugs in the Treatment of Chronic Pain Psychedelic drugs are currently being evaluated for their efficacy in treating several neuropsychiatric conditions and may have a potential role as treatments for chronic pain. This panel session will explore the potential role that psychedelic drugs… Read More

Prescription Medicines

4th Annual Neuropsychiatric Drug Development Summit

SEPTEMBER 29–30, 2021 | VIRTUAL EVENT Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates Clinical & Regulatory Challenges in Developing Psychedelics as Therapeutics Designing clinical trials that meet regulatory requirements without inadvertently stifling market access Managing the impact of CSA Schedule 1 status during development Building an optimal… Read More

Prescription Medicines

REL-1017 (esmethadone) Showed No Reinforcing Properties Compared to Oxycodone in Rat Self-Administration Study

Henningfield J, Gauvin D, Bifari F, Fant R, Caron J, Buchhalter A, Ashworth J, Pappagallo M, Folli F, Manfredi PL REL-1017 (esmethadone; dextromethadone) is an NMDAR channel blocker with a preference for hyperactive channels and has twenty-fold lower activity at the μ(mu)-opioid receptor than racemic methadone. REL-1017 is being developed for treatment of Major Depressive… Read More

Prescription Medicines

Meeting the Challenge of the Psychedelics and CNS Drugs with Novel Mechanisms – Building on the Foundation of the FDA 2017 Guidance on the Assessment of Abuse Potential

Chair/Speaker David Heal, PhD, DSc, FRSC, FBPhS, Executive Director, DevelRx Ltd. Speakers Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates Charles France, PhD, Robert A. Welch Distinguished University Chair in Chemistry, Professor of Pharmacology, and Professor of Psychiatry, UT Health San Antonio, Long School of Medicine, Department of Pharmacology Judy… Read More

Prescription Medicines

REL-1017 (esmethadone) Demonstrates No Withdrawal Effects or Evidence of Physical Dependence in a Rat Study

Gauvin D, Henningfield JE, Fant RV, Buchhalter AR, Ashworth J, Caron J, Pappagallo M, Bifari F, Folli F, Manfredi PL REL-1017 (esmethadone) is a novel NMDA channel blocker in development for major depressive disorder (MDD). REL-1017 has twenty-fold lower affinity than levomethadone at the mu-opioid receptor. According to a 2019 DEA statement, “The d-isomer lacks… Read More

Prescription Medicines

The 2020 CPDD Membership Survey: A New Approach to Assessing Diversity and Inclusion in Scientific Organizations

Fields S, Henningfield J, Regan T, Correa-Fernandez V, de Dios M, Garcia-Romeu A, Heads A, Hood C, Hudzik T, Moreland A, Skinstad A Advancing equity, inclusion and diversity is vital to increase innovation and the excellence of science as well at its relevance to societal and public health needs. This survey was developed to support… Read More

Prescription Medicines

Results of the 2020 CPDD Membership Survey: We Are More Diverse Than Suggested by Earlier Survey Approaches

Hood C, Garcia-Romeu A, Moreland A, Fields S, Henningfield JE, Correa-Fernandez V, de Dios M, Heads A, Hudzik T, Regan R, Skinstad A. Efforts to advance equity, inclusion, and diversity within CPDD are vital to increasing innovation and excellence in addiction science and relevance to societal and public health needs. This project examines openended responses… Read More